| Baseline Characteristic . | HR . | 95% CI . | P Value . |
|---|---|---|---|
| Sex | |||
| Male | — | — | |
| Female | 1.22 | 0.71-2.09 | .5 |
| Age | |||
| <18 y | — | — | |
| ≥18 y | 0.33 | 0.14-0.78 | .01 |
| Weight, kg | 1.00 | 0.98-1.02 | .9 |
| Starting dose | |||
| 5 mg/kg | — | — | |
| 10 mg/kg | 0.03 | 0.01-0.09 | <.001 |
| Diagnosis | |||
| CD | — | — | |
| IBD-U | 0.00 | 0.00-∞ | >.9 |
| UC | 0.95 | 0.34-2.64 | >.9 |
| Baseline steroid | |||
| No | — | — | |
| Prednisone | 1.37 | 0.66-2.84 | .4 |
| Budesonide | 2.97 | 1.28-6.93 | .01 |
| Baseline immunomodulators | |||
| No | — | — | |
| MTX | 1.66 | 0.35-7.97 | .5 |
| 6-MP | 1.12 | 0.29-4.32 | .9 |
| AZA | 3.63 | 0.44-30.1 | .2 |
| Disease severitya | 1.07 | 0.77-1.50 | .7 |
| Prior surgery | 0.00 | 0.00-∞ | >.9 |
| Albumin | 0.44 | 0.25-0.76 | .003 |
| Baseline Characteristic . | HR . | 95% CI . | P Value . |
|---|---|---|---|
| Sex | |||
| Male | — | — | |
| Female | 1.22 | 0.71-2.09 | .5 |
| Age | |||
| <18 y | — | — | |
| ≥18 y | 0.33 | 0.14-0.78 | .01 |
| Weight, kg | 1.00 | 0.98-1.02 | .9 |
| Starting dose | |||
| 5 mg/kg | — | — | |
| 10 mg/kg | 0.03 | 0.01-0.09 | <.001 |
| Diagnosis | |||
| CD | — | — | |
| IBD-U | 0.00 | 0.00-∞ | >.9 |
| UC | 0.95 | 0.34-2.64 | >.9 |
| Baseline steroid | |||
| No | — | — | |
| Prednisone | 1.37 | 0.66-2.84 | .4 |
| Budesonide | 2.97 | 1.28-6.93 | .01 |
| Baseline immunomodulators | |||
| No | — | — | |
| MTX | 1.66 | 0.35-7.97 | .5 |
| 6-MP | 1.12 | 0.29-4.32 | .9 |
| AZA | 3.63 | 0.44-30.1 | .2 |
| Disease severitya | 1.07 | 0.77-1.50 | .7 |
| Prior surgery | 0.00 | 0.00-∞ | >.9 |
| Albumin | 0.44 | 0.25-0.76 | .003 |
Abbreviations: 6-MP, 6-mercaptopurine; ALB, albumin; AZA, azathioprine; CD, Crohn’s disease; CI, confidence interval; HR, hazard ratio; IBD-U, inflammatory bowel disease unclassified; MTX, methotrexate; UC, ulcerative colitis.
Mayo: remission = 0-1; mild disease = 2-4; moderate disease = 5-6; severe disease = 7-9; or Harvey-Bradshaw index: remission = <5; mild disease = 5-7; moderate disease = 8-16; severe disease = >16.
| Baseline Characteristic . | HR . | 95% CI . | P Value . |
|---|---|---|---|
| Sex | |||
| Male | — | — | |
| Female | 1.22 | 0.71-2.09 | .5 |
| Age | |||
| <18 y | — | — | |
| ≥18 y | 0.33 | 0.14-0.78 | .01 |
| Weight, kg | 1.00 | 0.98-1.02 | .9 |
| Starting dose | |||
| 5 mg/kg | — | — | |
| 10 mg/kg | 0.03 | 0.01-0.09 | <.001 |
| Diagnosis | |||
| CD | — | — | |
| IBD-U | 0.00 | 0.00-∞ | >.9 |
| UC | 0.95 | 0.34-2.64 | >.9 |
| Baseline steroid | |||
| No | — | — | |
| Prednisone | 1.37 | 0.66-2.84 | .4 |
| Budesonide | 2.97 | 1.28-6.93 | .01 |
| Baseline immunomodulators | |||
| No | — | — | |
| MTX | 1.66 | 0.35-7.97 | .5 |
| 6-MP | 1.12 | 0.29-4.32 | .9 |
| AZA | 3.63 | 0.44-30.1 | .2 |
| Disease severitya | 1.07 | 0.77-1.50 | .7 |
| Prior surgery | 0.00 | 0.00-∞ | >.9 |
| Albumin | 0.44 | 0.25-0.76 | .003 |
| Baseline Characteristic . | HR . | 95% CI . | P Value . |
|---|---|---|---|
| Sex | |||
| Male | — | — | |
| Female | 1.22 | 0.71-2.09 | .5 |
| Age | |||
| <18 y | — | — | |
| ≥18 y | 0.33 | 0.14-0.78 | .01 |
| Weight, kg | 1.00 | 0.98-1.02 | .9 |
| Starting dose | |||
| 5 mg/kg | — | — | |
| 10 mg/kg | 0.03 | 0.01-0.09 | <.001 |
| Diagnosis | |||
| CD | — | — | |
| IBD-U | 0.00 | 0.00-∞ | >.9 |
| UC | 0.95 | 0.34-2.64 | >.9 |
| Baseline steroid | |||
| No | — | — | |
| Prednisone | 1.37 | 0.66-2.84 | .4 |
| Budesonide | 2.97 | 1.28-6.93 | .01 |
| Baseline immunomodulators | |||
| No | — | — | |
| MTX | 1.66 | 0.35-7.97 | .5 |
| 6-MP | 1.12 | 0.29-4.32 | .9 |
| AZA | 3.63 | 0.44-30.1 | .2 |
| Disease severitya | 1.07 | 0.77-1.50 | .7 |
| Prior surgery | 0.00 | 0.00-∞ | >.9 |
| Albumin | 0.44 | 0.25-0.76 | .003 |
Abbreviations: 6-MP, 6-mercaptopurine; ALB, albumin; AZA, azathioprine; CD, Crohn’s disease; CI, confidence interval; HR, hazard ratio; IBD-U, inflammatory bowel disease unclassified; MTX, methotrexate; UC, ulcerative colitis.
Mayo: remission = 0-1; mild disease = 2-4; moderate disease = 5-6; severe disease = 7-9; or Harvey-Bradshaw index: remission = <5; mild disease = 5-7; moderate disease = 8-16; severe disease = >16.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
